Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas
article
OA: closed
CC0
⤵ 4 in-corpus citations
AI-generated summary
This study examined hysterectomy specimens from 100 women treated with ulipristal acetate for uterine leiomyomas, finding progesterone receptor modulators-associated endometrial changes in 59% of cases, predominantly focally and within 4 weeks of treatment discontinuation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Ulipristal acetate (UPA) is used to treat leiomyomas, and its effect on the endometrium has been studied in biopsy material. Reversible histologic modifications were found, named progesterone receptor modulators-associated endometrial changes (PAEC). However, hysterectomies from patients treated with UPA have not been analyzed. For the first time, we examined surgical specimens from 100 leiomyoma-treated patients for UPA-related endometrial changes. We analyzed the distribution of lesions, involution after treatment, and the relationship between type and extent of lesions and dosage. Clinically, 72 patients were treated with 1 cycle of UPA; 23 patients with 2 cycles, and 5 with 3 cycles. A total of 66 patients underwent surgery in the first 4 wk after treatment, 24 were operated between 5 and 12 wk after discontinuation of UPA, and 10 after more than 12 wk after the last cycle, up to a maximum of 32 wk. Histologically normal endometria were found in 41 cases and PAEC in 59 cases. PAEC consisted of irregular, cystic glands showing a flattened secretory-like epithelium with vacuolation, coexisting mitoses and apoptosis, and were found focally within cyclic endometria in 51 cases. Only in 8 cases did diffuse PAEC involve the whole endometrium, transforming it into a thick spongy cushion. PAEC also occurred in adenomyosis. There was no relationship between dosage and type and extent of lesions. Diffuse PAEC, which usually presents differential diagnoses with hyperplasia, occurred in only 8 cases, being only present during the first 4 wk after discontinuation of treatment and was independent of the number of cycles administered.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator 2009
- Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report 2016
- Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids 2014
Cited by (4)
- Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? 2018
- A critical review of recent advances in the diagnosis, classification, and management of uterine adenomyosis 2019
- Ulipristal Acetate Prior to Surgery for Endometriosis 2020
- Navigating through perplex morphologic changes after exogenous hormone usage 2021
References (16)
- Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator via openalex
- Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report via openalex
- Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids via openalex
- W2026392453 via openalex
- W2076339517 via openalex
- W2106587450 via openalex
- W2156957181 via openalex
- W1969068003 via openalex
- W2281814248 via openalex
- W2550843123 via openalex
- W2581546164 via openalex
- W6693730162 via openalex
- W6732527681 via openalex
- W2268010420 via openalex
- W1996100965 via openalex
- W2026045071 via openalex
Cited by (4)
- Navigating through perplex morphologic changes after exogenous hormone usage 2021
- Ulipristal Acetate Prior to Surgery for Endometriosis 2020
- A critical review of recent advances in the diagnosis, classification, and management of uterine adenomyosis 2019
- Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? 2018
Source provenance
- europepmc
- last seen: 2026-06-13T06:22:48.782012+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:20:13.663096+00:00
License: CC0
· commercial use OK